filmov
tv
Metastatic Breast Cancer Circulating Cancer Stem Cells (MBCCSC)
Показать описание
Liquid Biopsy Literacy:
This is the only distinguished medical oncology research page that will teach you about SFRP4 liquid biopsy clinical trials better than universities and hospitals.
We have solutions to improve treatments. Here's something new and promising! With the potential of Medonctherapeutics' stem CTC technology and the initiation of Wnt antagonist: secreted frizzled-related protein 4 (SFRP4) treatment, we're looking at a hopeful future for cancer diagnosis. We're proud to be the distinguished pioneer in leading the SFRP4 liquid biopsy products in Perth, Western Australia, with an academic research patent portfolio track record for commercial projects. I initiated such research in a multidisciplinary research team collaboration setting between SCGH and Curtin University in 2017-2019 with funding attraction. More information regarding this topic can be found in Cancers by Vanathi et al., 2019.
Our upcoming advanced stem CTC technology, tested on twenty healthy volunteers from 2017-2019, has shown promising results for breast cancer and solid tumour diagnosis and treatments. The future of cancer treatment is looking bright, with the potential to prevent metastasis and tumour relapse with automation and high-throughput drug screening options for cell therapies and genetic testing.
A recent Chinese study on 48 patients with stage IV breast invasive ductal cancer has reported significant findings. The study tested circulating tumour cells and circulating cancer stem cells, using them as independent OS and PFS prognostic markers for palliative first-line chemotherapy of trastuzumab plus docetaxel, paclitaxel plus gemcitabine, and doxorubicin plus cyclophosphamide using CT and positron emission tomography (PET) imaging response. In my understanding, this is a crucial advancement in breast cancer diagnosis and its treatment.
Limitation and future direction
This is a small study on 48 patients limiting power statistics.
It is lacking the CTC purity and viability data.
Just CCSC—CD 133 marker baseline count testing data were obtained. Demonstrating stemness potential as spheres, will be a better way to represent the aggressiveness of cancer for CTC drug development along with other breast cancer Her 2, CA 153, CA 199, and braca 1 protein/gene expressions.
Targeting live CTC/CCSC and drug testing on the patient CCSC/tumoursphere before administering patients, avoiding drug and imaging toxicity and saving treatment failure costs is a more sensible and powerful strategy. It is a good study for future improvements, like our NHMRC standards pilot clinical trial, which stands out from other CTC research and commercial global competitors.
Contact us and book now at
The CTC lines, circulating cancer stem cell spheres, and organoids hold promise for future tailored SFRP4 and Wnt antagonist treatments.
Medical oncology research content writing, video recording and editing by Dr. Vanathi Perumal
Check out my other helpful breast cancer CTC links:
Disclaimer
It is unrelated to Curtin University-Sir Charles Gairdner Hospital's radiation oncology research products.
This podcast is intended only for educational and informational purposes, not as medical advice/device. We offer on-call medical oncology scientists services for liquid biopsy products through our website and Zoom/phone call meetings. Book for professional research consultations/meetings and grant proposals, manuscript writing, medical writing, clinical trial study protocols, and rebuttals at an hourly rate of 85A$. The business is in an initial phase; no refund policy applies. They are offered under CDA or NDA. Administrative charges apply for using the medonctherapeutics method and testing Australian IP CTC research liquid biopsy portfolio online services. Charges apply for testing unpublished all-in-one capability stem CTC and spheres technology on clinical samples.
References:
Chun-Hui Lee et al.; BMC Cancer. 2019 Dec 2;19(1):1167
Monika et al; Oncotarget .2016 Jul 26;7(30):48143-48154
Nicola Aceto et al; Cell 2014 Aug 28;158(5):1110-1122
Follow us on social media:
This is the only distinguished medical oncology research page that will teach you about SFRP4 liquid biopsy clinical trials better than universities and hospitals.
We have solutions to improve treatments. Here's something new and promising! With the potential of Medonctherapeutics' stem CTC technology and the initiation of Wnt antagonist: secreted frizzled-related protein 4 (SFRP4) treatment, we're looking at a hopeful future for cancer diagnosis. We're proud to be the distinguished pioneer in leading the SFRP4 liquid biopsy products in Perth, Western Australia, with an academic research patent portfolio track record for commercial projects. I initiated such research in a multidisciplinary research team collaboration setting between SCGH and Curtin University in 2017-2019 with funding attraction. More information regarding this topic can be found in Cancers by Vanathi et al., 2019.
Our upcoming advanced stem CTC technology, tested on twenty healthy volunteers from 2017-2019, has shown promising results for breast cancer and solid tumour diagnosis and treatments. The future of cancer treatment is looking bright, with the potential to prevent metastasis and tumour relapse with automation and high-throughput drug screening options for cell therapies and genetic testing.
A recent Chinese study on 48 patients with stage IV breast invasive ductal cancer has reported significant findings. The study tested circulating tumour cells and circulating cancer stem cells, using them as independent OS and PFS prognostic markers for palliative first-line chemotherapy of trastuzumab plus docetaxel, paclitaxel plus gemcitabine, and doxorubicin plus cyclophosphamide using CT and positron emission tomography (PET) imaging response. In my understanding, this is a crucial advancement in breast cancer diagnosis and its treatment.
Limitation and future direction
This is a small study on 48 patients limiting power statistics.
It is lacking the CTC purity and viability data.
Just CCSC—CD 133 marker baseline count testing data were obtained. Demonstrating stemness potential as spheres, will be a better way to represent the aggressiveness of cancer for CTC drug development along with other breast cancer Her 2, CA 153, CA 199, and braca 1 protein/gene expressions.
Targeting live CTC/CCSC and drug testing on the patient CCSC/tumoursphere before administering patients, avoiding drug and imaging toxicity and saving treatment failure costs is a more sensible and powerful strategy. It is a good study for future improvements, like our NHMRC standards pilot clinical trial, which stands out from other CTC research and commercial global competitors.
Contact us and book now at
The CTC lines, circulating cancer stem cell spheres, and organoids hold promise for future tailored SFRP4 and Wnt antagonist treatments.
Medical oncology research content writing, video recording and editing by Dr. Vanathi Perumal
Check out my other helpful breast cancer CTC links:
Disclaimer
It is unrelated to Curtin University-Sir Charles Gairdner Hospital's radiation oncology research products.
This podcast is intended only for educational and informational purposes, not as medical advice/device. We offer on-call medical oncology scientists services for liquid biopsy products through our website and Zoom/phone call meetings. Book for professional research consultations/meetings and grant proposals, manuscript writing, medical writing, clinical trial study protocols, and rebuttals at an hourly rate of 85A$. The business is in an initial phase; no refund policy applies. They are offered under CDA or NDA. Administrative charges apply for using the medonctherapeutics method and testing Australian IP CTC research liquid biopsy portfolio online services. Charges apply for testing unpublished all-in-one capability stem CTC and spheres technology on clinical samples.
References:
Chun-Hui Lee et al.; BMC Cancer. 2019 Dec 2;19(1):1167
Monika et al; Oncotarget .2016 Jul 26;7(30):48143-48154
Nicola Aceto et al; Cell 2014 Aug 28;158(5):1110-1122
Follow us on social media:
0:02:35
0:55:07
0:01:17
0:05:57
0:00:52
0:39:15
0:07:34
0:19:46
0:29:16
0:50:22
1:01:16
0:04:46
1:03:19
0:28:21
0:08:21
1:04:51
0:02:14
1:52:27
0:57:52
0:59:38
1:08:09
0:35:13
0:38:11
0:02:39